AndroGel and Hormonal Contraceptives: Drug Interaction, Risks, and Clinical Guidance

Who Faces This Interaction and Why It Matters

Two populations encounter the AndroGel-hormonal contraceptive interaction. The first and most common: female sexual partners of men prescribed testosterone gel for hypogonadism. The second: transmasculine or nonbinary patients using testosterone gel who also take a hormonal contraceptive for pregnancy prevention or menstrual suppression.

Each scenario carries different risks. For female partners, the danger is inadvertent virilization from secondary testosterone transfer through direct skin contact [1]. For transmasculine patients using both medications simultaneously, the concern shifts to pharmacodynamic interference, where exogenous testosterone may blunt estrogen- or progestin-mediated contraceptive effects, and shared hepatic metabolism may alter drug levels [2].

The FDA's prescribing information for AndroGel includes a boxed warning: "Secondary exposure to testosterone in children and women can occur with the use of testosterone gel in men. Cases of secondary exposure have been reported in children and women" [1]. Between 2000 and 2009, the FDA received reports of virilization in female partners and children exposed to topical testosterone products, including cases of clitoral enlargement, increased body hair, and deepened voice [3]. These effects were sometimes irreversible.

This is not a theoretical risk. It has regulatory consequences.

Pharmacokinetic Overlap: CYP3A4 and SHBG

Testosterone is metabolized primarily by the cytochrome P450 3A4 (CYP3A4) enzyme system in the liver, with secondary contributions from CYP3A5 and 5-alpha reductase [4]. Ethinyl estradiol (EE), the synthetic estrogen in most combined oral contraceptives, is also a CYP3A4 substrate and a weak inhibitor of the enzyme [5].

When both compounds are present in the same individual, competitive CYP3A4 binding can slow testosterone clearance. The clinical magnitude of this effect is modest. A pharmacokinetic study of oral testosterone undecanoate co-administered with EE-containing contraceptives showed no statistically significant change in testosterone AUC, though free testosterone rose slightly due to SHBG changes [6]. Topical testosterone (as in AndroGel) bypasses first-pass hepatic metabolism, which further attenuates this interaction.

The more relevant pharmacokinetic effect runs in the opposite direction. Exogenous testosterone reduces sex hormone-binding globulin (SHBG) concentrations. SHBG binds both testosterone and estradiol. A drop in SHBG increases the free fraction of ethinyl estradiol. This does not typically enhance contraceptive efficacy. Instead, it raises the risk of estrogen-related side effects such as headache, nausea, and venous thromboembolism [7].

Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) have a more clinically meaningful interaction with both drug classes than the two drugs have with each other [4]. Prescribers should screen the full medication list for potent CYP3A4 modulators before attributing any pharmacokinetic shift to the testosterone-contraceptive pairing alone.

Pharmacodynamic Conflict: Hormonal Opposition

Combined hormonal contraceptives work through three estrogen- and progestin-dependent mechanisms: suppression of the hypothalamic-pituitary-gonadal (HPG) axis to prevent ovulation, thickening of cervical mucus, and thinning of the endometrial lining [8]. Exogenous testosterone can oppose each of these.

Testosterone suppresses gonadotropins (LH and FSH) through negative feedback at the hypothalamus. This effect is dose-dependent. At replacement doses for male hypogonadism (50 to 100 mg of testosterone gel daily), gonadotropin suppression is profound in males. In female-bodied individuals, testosterone-driven gonadotropin suppression may or may not fully prevent ovulation. A 2014 study of 20 transmasculine patients on intramuscular testosterone found that 64% had persistent ovarian follicular activity on ultrasound despite amenorrhea [9].

That finding carries a direct contraceptive implication. Amenorrhea during testosterone use does not equal anovulation.

The Endocrine Society's 2017 clinical practice guideline for gender-dysphoric and gender-incongruent persons states: "Transgender men who have not had a hysterectomy and are sexually active with a partner who produces sperm should use a contraceptive method" [10]. The guideline does not endorse testosterone monotherapy as a contraceptive.

Progestin-only methods (hormonal IUDs, etonogestrel implants) sidestep most of the pharmacodynamic conflict because they do not rely on estrogen-mediated ovulation suppression as their primary mechanism. The levonorgestrel IUD (Mirena, 52 mg) achieves contraception mainly through local endometrial and cervical mucus effects, with ovulation still occurring in many cycles [8]. This local mechanism is less vulnerable to interference from systemic testosterone.

Secondary Exposure: The Highest-Severity Risk

For female partners of men using AndroGel, direct pharmacokinetic drug-drug interaction is not the issue. Secondary dermal transfer is.

Testosterone gel is designed to deliver drug through the stratum corneum. The same property that makes it effective for the patient makes it transferable. The AndroGel 1.62% prescribing information reports that skin-to-skin contact at the application site transferred measurable testosterone to female subjects in controlled studies [1]. Serum testosterone in female contacts rose up to 5-fold above baseline after 15 minutes of direct skin contact with the treated area before the gel dried.

A 2012 study published in the Journal of Clinical Endocrinology and Metabolism evaluated testosterone transfer from men using 1% testosterone gel. Female partners who had direct skin contact with the application area (shoulders, upper arms) within 2 hours of gel application showed a mean serum testosterone increase from 26 ng/dL to 55 ng/dL [11]. After the treated man wore a T-shirt covering the application site, transfer dropped to undetectable levels.

What does transferred testosterone do to a woman on hormonal contraceptives? Three effects are possible. First, androgenic side effects (acne, hirsutism, voice deepening) from chronic low-level testosterone exposure. Second, pharmacodynamic blunting of contraceptive efficacy, as described above. Third, fetal virilization if contraception fails and pregnancy occurs during ongoing testosterone exposure. The FDA classifies testosterone as pregnancy category X [1].

Practical mitigation is straightforward. The FDA label recommends washing the application site with soap and water before anticipated skin-to-skin contact, or covering the site with clothing [1]. A 2009 FDA advisory committee review concluded that clothing barriers and hand-washing after application reduce secondary transfer to near-zero [3].

Monitoring Protocol for Concurrent Use

When a clinician identifies that a patient using AndroGel has a female partner on hormonal contraceptives, or when a transmasculine patient uses both medications, a structured monitoring plan reduces risk.

For female partners of male patients, the monitoring is primarily behavioral. Confirm that the patient applies gel to sites that can be covered by clothing (upper arms, shoulders, abdomen). Verify that the patient washes hands with soap and water immediately after application. Advise the partner to wash the contact area if unprotected skin-to-skin contact occurs before the gel has dried (minimum 2 hours, ideally 5 to 6 hours) [1]. If the female partner reports new-onset acne, facial hair growth, menstrual irregularity, or voice changes, check a serum total testosterone level.

For transmasculine patients on concurrent testosterone gel and hormonal contraceptives, monitoring is more intensive. Check serum total and free testosterone at baseline, 4 weeks, and every 6 to 12 months [10]. Measure SHBG to assess binding protein shifts. A total testosterone level consistently above 400 ng/dL in a patient with a uterus warrants a conversation about contraceptive adequacy. Progestin-only IUDs or implants are preferred over combined oral contraceptives because their local mechanism of action is less susceptible to androgenic interference [10].

A complete metabolic panel and fasting lipid profile at baseline and annually are reasonable given that both testosterone and ethinyl estradiol affect hepatic lipid metabolism, with testosterone tending to lower HDL and ethinyl estradiol tending to raise it [7]. The net effect is unpredictable and patient-specific.

Contraceptive Method Selection in the Context of Testosterone Use

Not all hormonal contraceptives interact with testosterone to the same degree. Method selection can minimize pharmacodynamic conflict.

The levonorgestrel intrauterine device (Mirena, Liletta) is the preferred option for transmasculine patients on testosterone, per both the Endocrine Society [10] and the American College of Obstetricians and Gynecologists [12]. Its local progestational effect on the endometrium and cervical mucus operates independently of systemic hormone levels. Placement does not require discontinuation of testosterone.

The etonogestrel subdermal implant (Nexplanon) offers similar advantages: a local-plus-systemic progestin effect, no estrogen component, and 3-year duration. Ovulation suppression with the implant is highly reliable (failure rate <0.1% in the first year), and testosterone at physiologic male levels does not appear to override this suppression [13].

Combined oral contraceptives (COCs) are the least preferred option. Their efficacy depends on consistent daily dosing, and the SHBG-lowering effect of testosterone increases free ethinyl estradiol levels, potentially amplifying thrombotic risk [7]. For transmasculine patients who also have migraine with aura or other estrogen contraindications, COCs are already excluded by standard prescribing guidelines [8].

Depot medroxyprogesterone acetate (DMPA, Depo-Provera) provides reliable ovulation suppression and does not interact pharmacokinetically with topical testosterone in a clinically meaningful way. Its chief drawback is a bone mineral density reduction with long-term use, which testosterone partially offsets through anabolic bone effects [14].

Patient Counseling: What to Tell Each Population

Counseling differs by clinical scenario.

For the male hypogonadism patient: "Your testosterone gel can transfer through skin contact to your partner. Apply the gel to an area you can cover with a shirt. Wash your hands right after application. If your partner will touch the application site, shower first or make sure the area has been covered by clothing for at least two hours. Your partner should tell her doctor if she notices new acne, hair growth, or a voice change."

For the transmasculine patient: "Testosterone alone is not birth control. Even if your period stops, you may still ovulate. If you are having sex that could result in pregnancy, use a separate contraceptive method. An IUD or implant is the most reliable option because it works locally and is not affected by your testosterone dose. Tell your prescriber about all the hormones you are taking so they can monitor your blood work."

These conversations should be documented in the chart and revisited at each follow-up visit, particularly after dose adjustments to either medication. A testosterone dose increase, for example from AndroGel 1.62% one pump (20.25 mg) to four pumps (81 mg), changes both the secondary transfer risk and the degree of gonadotropin suppression [1].

Patients prescribed testosterone gel who report a new sexual partner should receive repeat counseling. The FDA's Risk Evaluation and Mitigation Strategy (REMS) for testosterone gel products was proposed in 2009, and while a formal REMS was not ultimately mandated, the agency added the boxed warning and a Medication Guide requirement to reinforce secondary exposure precautions [3].